Company Filing History:
1 out of 1 
1 out of 28 
2 out of 832,912 Years Active: 2011-2013
Title: Innovations of Mike John Bickerdike
Introduction
Mike John Bickerdike is an accomplished inventor based in Auckland, New Zealand. He holds a total of four patents, showcasing his contributions to the field of pharmaceuticals and neuroprotection. His work focuses on developing innovative treatments for peripheral neuropathy and neurodegenerative conditions.
Latest Patents
Bickerdike's latest patents include "Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy." This invention provides methods for the therapeutic use of cyclic G-2-allylProline (cG-2-allylP) to treat various forms of peripheral neuropathy, including toxin-induced and diabetic peripheral neuropathy. The patent also covers the manufacture of medicaments, such as tablets and injectable solutions, containing cG-2-allylP. Another significant patent is for "Oral formulations of glycyl-2-methylprolyl-glutamate." This invention presents oral formulations of G-2MePE that demonstrate improved bioavailability compared to conventional aqueous formulations. Notably, microparticles and microemulsions of G-2MePE can exhibit remarkable neuroprotective effects, even inhibiting cerebral infarction in animal models of stroke.
Career Highlights
Throughout his career, Bickerdike has worked with various companies, including Neuron Pharmaceuticals Limited. His innovative approaches have led to significant advancements in the treatment of neurological conditions, making him a notable figure in the pharmaceutical industry.
Collaborations
Bickerdike has collaborated with esteemed colleagues, including Jingyuan Wen and Gregory Brian Thomas. Their combined expertise has contributed to the success of his inventions and the development of effective treatments.
Conclusion
Mike John Bickerdike's contributions to the field of pharmaceuticals through his innovative patents highlight his dedication to improving treatments for peripheral neuropathy and neurodegenerative diseases. His work continues to impact the medical community positively.